LSBCF (LakeShore Biopharma Co) DeferredTaxAndRevenue: $0.20 Mil (As of Mar. 2025)


What is LakeShore Biopharma Co DeferredTaxAndRevenue?

LakeShore Biopharma Co LSBCF DeferredTaxAndRevenue is $0.20 Mil as of Mar. 2025.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

LakeShore Biopharma Co's current deferred tax and revenue for the quarter that ended in Mar. 2025 was $0.20 Mil.

LakeShore Biopharma Co DeferredTaxAndRevenue Related Terms

LakeShore Biopharma Co DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co DeferredTaxAndRevenue Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
DeferredTaxAndRevenue
0.33 0.36 0.33 0.28 0.20

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only 0.33 0.32 0.28 0.23 0.20
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.20 Mil mean?
LakeShore Biopharma Co (LSBCF) has a DeferredTaxAndRevenue of $0.20 Mil as of Mar. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on LakeShore Biopharma Co.
Is LakeShore Biopharma Co's DeferredTaxAndRevenue too high?
LakeShore Biopharma Co's current DeferredTaxAndRevenue is $0.20 Mil.
How does LakeShore Biopharma Co's DeferredTaxAndRevenue compare to ACUT and PPCB?
LakeShore Biopharma Co's DeferredTaxAndRevenue of $0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on LakeShore Biopharma Co. LakeShore Biopharma Co's current DeferredTaxAndRevenue is $0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current DeferredTaxAndRevenue of $0.20 Mil. The current DeferredTaxAndRevenue is $0.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current DeferredTaxAndRevenue is $0.20 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.